ABBV240719C170000
- 0.70
- -0.45-39.13%
AbbVie Newsroom
AbbVie Looks to Add an Eighth Indication for JAK Inhibitor Rinvoq
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
Should You Be Excited About AbbVie Inc.'s (NYSE:ABBV) 75% Return On Equity?
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
AbbVie Earnings Preview: What to Expect
Express News | AbbVie Submits Applications To FDA And EMA For New Indication Of Upadacitinib (RINVOQ) For Treatment Of Giant Cell Arteritis; Supported By Phase 3 SELECT-GCA Study Showing Sustained Remission And Consistent Safety Profile
Express News | Abbvie Submits Regulatory Applications to FDA and EMA for Upadacitinib (Rinvoq®) in Giant Cell Arteritis
Dividend Roundup: Procter & Gamble, Costco, CVS Health, Colgate-Palmolive, and More
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Giant Cell Arteritis
Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12
AbbVie To Go Ex-Dividend On July 15th, 2024 With 1.55 USD Dividend Per Share
July 11th (Eastern Time) - $AbbVie(ABBV.US)$ is trading ex-dividend on July 15th, 2024.Shareholders of record on July 15th, 2024 will receive 1.55 USD dividend per share on August 15th, 2024. The ex-
AbbVie (ABBV) Gains As Market Dips: What You Should Know
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical
AbbVie Unusual Options Activity
Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:ABBV).And retail traders should know.We noticed this today when the positions showed up on publicly available
AbbVie Is Maintained at Overweight by Morgan Stanley
AbbVie Is Maintained at Overweight by Morgan
AbbVie Price Target Raised to $196.00/Share From $191.00 by Morgan Stanley
AbbVie Price Target Raised to $196.00/Share From $191.00 by Morgan
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 15.59% Morgan Stanley $191 → $196 Maintains Overweight 07/09/2024 17.95% Cantor Fitzgerald $200
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?
Here Is What to Know Beyond Why AbbVie Inc. (ABBV) Is a Trending Stock
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191
AbbVie (ABBV) has an average rating of outperform and price targets ranging from $168 to $203, according to analysts by Capital IQ.Price: 168.26, Change: +0.12, Percent Change: +0.07